BAM
IART icon

Belpointe Asset Management’s Integra LifeSciences IART Stock Holding History

Belpointe Asset Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-417
Closed -$23.9K – 1826
2023
Q1 		$23.9K Buy
417
+218
+110% +$12.3K ﹤0.01% 2204
2022
Q4 		$11.2K Buy
+199
New +$10.1K ﹤0.01% 2556

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belpointe Asset Management's IART Position: Q2 2023 in Review

Belpointe Asset Management sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 417 shares — an estimated $23.9K sold.

Belpointe Asset Management first reported a position in IART in Q4 2022 and held it in 2 quarters. The position peaked at $23.9K in Q1 2023. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

  • Belpointe Asset Management reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 417 Integra LifeSciences shares in Q2 2023, an estimated $23.9K.
  • Belpointe Asset Management first reported a position in Integra LifeSciences in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Integra LifeSciences position peaked at $23.9K in Q1 2023.
  • 283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.